It is considering clinical trials to verify the new drug candidate GV1001, which GemVax is developing as a treatment for Alzheimer's disease, for the rare disease progressive supranuclear pals.

However, the Central Pharmaceutical Affairs Review Committee, an expert advisory body from the MFDS, has postponed the judgment that additional data are needed.

The minutes of the Central Pharmaceutical Affairs Review Committee released by the MFDS on the 20th are as follows.

The meeting held on the 11th of last month was to consult with GV1001 on the feasibility of conducting a clinical trial for patients with progressive supranuclear pals.

GV1001 is a treatment for